Loading
Innoviva, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Jun 2023.
Innoviva, Inc.: what insiders have been doing
Innoviva, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 12 filings signed by 3 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
With 12 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. Over the whole record (from 2016), the tally stands at 7 purchases and 5 sales. The 10-K for the year ended 31 December 2025 shows 411.3 m USD of revenue and 271.2 m USD of net income.
Over the last twelve months, not one insider purchase of Innoviva, Inc. stock was filed. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
88
Thresholds
n/a
Buy Volume
€5M
7 ops. · all time
Sell Volume
€323M
5 ops. · all time
Who traded when
BuySaleAlexander J. Denner1 sale
Since the insiders bought
- +10.3%Entry US$13.96 · Close at T+365 US$15.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 105 of 24,148 companies
90.4
score / 100
Value91
Quality90
FCF yld12%
Earn yld18%
EV/EBITDA4.8x
ROE37%
Gross mgn81%
Net mgn66%
Debt/EBITDA0.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$20.78
Analyst consensus
5 analysts1.80/5
US$18.00Target US$35.00(+68%)US$46.00
Income statement
RevenueUS$411.3M
Gross profitUS$333.9M81% margin
EBITDAUS$369.8M90% margin
Net incomeUS$271.2M81.2% margin
Valuation
PER (trailing)4.9x
PER (forward)9.5x
P/Book1.2x
Beta0.38
Balance sheet & cash
Market capUS$1.5B
Total debtUS$269M
Free Cash FlowUS$186.4M
Debt / Equity27%
Profitability & ownership
ROE36.7%
ROA6.9%
% insiders1.0%
% institutions108.6%
Last declaration on 24 August 2026
Declarations88 total
558 shares@ US$21.000.0008% mcap1.2% of flowCommon StockSEC:0001193125-26-363610:0
1,130 shares@ US$21.000.0015% mcap2.9% of flowCommon StockSEC:0001193125-26-363608:0
1,127 shares@ US$21.000.0015% mcap3.1% of flowCommon StockSEC:0001193125-26-363611:0
559 shares@ US$22.240.0007% mcap1.3% of flowCommon StockSEC:0001193125-26-236913:1
1,123 shares0Common StockSEC:0001193125-26-236913:0
1,244 shares@ US$23.393.0% of flowCommon StockSEC:0001193125-26-067029:0
2,986 shares@ US$23.398.4% of flowCommon StockSEC:0001193125-26-067024:0
2,460 shares@ US$23.397.5% of flowCommon StockSEC:0001193125-26-067022:0
992 shares@ US$21.162.8% of flowCommon StockSEC:0001104659-25-115425:0
604 shares0Common StockSEC:0001104659-25-115427:0
1,860 shares0Common StockSEC:0001104659-25-107234:0
27,609 shares@ US$18.1152.2% of flowCommon StockSEC:0001104659-25-107236:0
237 shares@ US$19.950.5% of flowCommon StockSEC:0001104659-25-081891:0
991 shares@ US$19.952.6% of flowCommon StockSEC:0001104659-25-081888:0
1,353 shares0Common StockSEC:0001104659-25-051998:0
992 shares@ US$18.782.5% of flowCommon StockSEC:0001104659-25-052002:0
12,077 shares0Common StockSEC:0001104659-25-051746:0
12,077 shares0Common StockSEC:0001104659-25-051748:0
12,077 shares0Common StockSEC:0001104659-25-051749:0
12,077 shares0Common StockSEC:0001104659-25-051747:0
37,377 shares@ US$17.3984.4% of flowCommon StockSEC:0000899140-25-000472:0
8,938 shares@ US$18.0823.6% of flowCommon StockSEC:0000899140-25-000474:0
10,569 shares@ US$18.0821.9% of flowCommon StockSEC:0000899140-25-000473:0
151,175 shares@ US$17.629132.3% of flowCommon Stock, par value $0.01 per shareSEC:0000899140-25-000405:0
2,565 shares@ US$18.076.8% of flowCommon StockSEC:0000899140-25-000361:0
25 of 88 declarations
About Innoviva, Inc.
Innoviva, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. For international investors, it should not be viewed as a conventional R&D-heavy biotech. Instead, Innoviva operates a hybrid model that combines a core royalty portfolio, a specialty critical care and infectious disease platform, and strategic investments in healthcare assets. In its latest annual report, the company explicitly describes itself around those three pillars, which gives it a business profile that is part royalty platform, part commercial therapeutics company, and part healthcare capital allocator. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1080014/000095017025027864/inva-20241231.htm?utm_source=openai))
Innoviva’s corporate history reflects a meaningful strategic shift over time. The company notes that it spun off its research and development operations in June 2014, after which it increasingly positioned itself as a royalty manager and portfolio builder rather than a traditional drug-discovery company. That transition is important for understanding the equity story: the company has sought to broaden its revenue base beyond legacy royalties and into commercial healthcare assets, while preserving the cash-generating characteristics of partnered products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1080014/000119312523127519/d397186dars.pdf?utm_source=openai))
Read moreShow less
The royalty engine is anchored by respiratory assets partnered with GSK, most notably RELVAR/BREO ELLIPTA and ANORO ELLIPTA. These products provide exposure to global product sales through contractual royalty streams, which can offer more revenue visibility than a pure development-stage biotech. At the same time, Innoviva remains dependent on its partner’s commercial execution and on the durability of the underlying respiratory franchise, so the competitive position is best described as asset-backed and cash-flow oriented rather than innovation-led in the classic biotech sense. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1080014/000095017025027864/inva-20241231.htm?utm_source=openai))
On the operating side, Innoviva Specialty Therapeutics focuses on hospital-based critical care and infectious disease therapies. Its marketed products include GIAPREZA, XERAVA, and XACDURO, and the company also entered into an exclusive U.S. distribution and license agreement for ZEVTERA in December 2024. In addition, Innoviva has been working toward a U.S. NDA submission for zoliflodacin, a potential single-dose oral treatment for uncomplicated gonorrhea. This portfolio indicates a targeted strategy in high-unmet-need hospital and anti-infective markets, where commercial differentiation can be meaningful if clinical value is clear. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1080014/000095017025027864/inva-20241231.htm?utm_source=openai))
Geographically, Innoviva is primarily a U.S. company, with headquarters in the United States and a commercial footprint centered on the domestic market for its specialty therapeutics business. Its royalty income, however, is tied to global partner sales, so the company has indirect international exposure through GSK’s worldwide commercialization of respiratory products. Recent milestones include the 2023 U.S. approval and launch of XACDURO, the December 2024 ZEVTERA agreement, and management’s early-2025 commentary highlighting year-over-year growth in both the royalty portfolio and therapeutics business. For investors, Innoviva is best characterized as a niche healthcare compounder with a mixed revenue model, combining royalty cash flows with selective operating assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1080014/000095017025027864/inva-20241231.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
